Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 [Yahoo! Finance]
Vincerx Pharma, Inc. (VINC)
Company Research
Source: Yahoo! Finance
The company has seen encouraging safety, efficacy, and tolerability results in the study, with one patient achieving a complete remission. To focus resources on VIP943, Vincerx will reduce its workforce by 55% and consider options such as out-licensing, mergers, and asset sales. The company had $8.4 million in cash, cash equivalents, and marketable securities as of October 31, 2024. Also Exploring Strategic Alternatives to Complement Fundraising Efforts PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the Company's novel CD123-targeted antibody-drug conjugate (ADC) developed with the Company's next-generation VersAptx™ platform. “We believe VIP943 is a highly differentiated
Show less
Read more
Impact Snapshot
Event Time:
VINC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VINC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VINC alerts
High impacting Vincerx Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
VINC
News
- $TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - VINC, VCSA, MRNS, MHLDAccesswire
- VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to ShareholdersBusiness Wire
- Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public ShareholdersBusiness Wire
- Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.GlobeNewswire
- Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943GlobeNewswire
VINC
Analyst Actions
- 10/8/24 - Leerink Partners
VINC
Sec Filings
- 12/27/24 - Form 8-K
- 12/27/24 - Form 424B5
- 12/10/24 - Form DEF
- VINC's page on the SEC website